{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-23-000063","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.451731+00:00","generated_at":"2026-06-14T18:23:53.046701+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunovant reports FY2023 net loss $211M; IMVT-1402 IND cleared, Phase 1 started","bullets":["Net loss of $59.4M ($0.46/share) for Q4 FY2023 vs $47.2M ($0.41) a year ago.","Full-year net loss $211.0M ($1.71/share) vs $156.7M ($1.43); cash $376.5M funding into H2 2025.","R&D expenses rose 61% YoY to $160.3M, driven by batoclimab and IMVT-1402 programs.","FDA IND and MEDSAFE CTA cleared for IMVT-1402; Phase 1 trial enrolling in New Zealand.","Initial Phase 1 data from single-ascending dose expected Aug/Sep 2023; MAD data Oct/Nov 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-23-000063","json":"https://secwatch.observer/filing/0001764013-23-000063.json","markdown":"https://secwatch.observer/filing/0001764013-23-000063.md","text":"https://secwatch.observer/filing/0001764013-23-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/0001764013-23-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/imvt-20230522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:23:53.046701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"717c7ae4affb16006c16db3f91e0aca45e282674","claim":"Immunovant, Inc. reported the three months ended March 31, 2023 results: net income $59.4 million, EPS $0.46 per common share.","evidence_excerpt":"Net loss was $59.4 million ($0.46 per common share) for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/0001764013-23-000063-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"$59.4 million"},{"label":"EPS","value":"$0.46 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"aa075fde63c73c22605d9cc3f58a148866eb1db4","claim":"Immunovant, Inc. reported the fiscal year ended March 31, 2023 results: net income $211.0 million, EPS $1.71 per common share.","evidence_excerpt":"Net loss was $211.0 million ($1.71 per common share) for the fiscal year ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/0001764013-23-000063-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended March 31, 2023"},{"label":"Net income","value":"$211.0 million"},{"label":"EPS","value":"$1.71 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}